Sartorius AG Vorz-Inhaber-Akt ohne Stimmrecht
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€919.00 | Shgl | Vsvdmgfdc |
Sartorius AG Experiencing Tough 2023 Reset, but Long-Term Story Intact
Business Strategy and Outlook
Sartorius AG is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. It offers products and services for life science labs and bioprocessing. For bioprocessing, Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.